Information Provided By:
Fly News Breaks for November 19, 2019
Nov 19, 2019 | 07:09 EDT
H.C. Wainwright analyst Ed Arce raised his price target for Dicerna Pharmaceuticals (DRNA) to $30 from $22 after the company after announced a new strategic alliance with Novo Nordisk (NVO). The analyst sees "favorable deal terms embedded with optionality." He continues to view Dicerna as a "core, pure-play holding" in the greater nucleic acid therapy space and reiterates a Buy rating on the shares.
News For DRNA;NVO From the Last 2 Days
There are no results for your query DRNA;NVO